W.G. Shaheen & Associates DBA Whitney & Co Grows Holdings in AbbVie Inc. $ABBV

W.G. Shaheen & Associates DBA Whitney & Co increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 147.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,569 shares of the company’s stock after purchasing an additional 11,069 shares during the quarter. W.G. Shaheen & Associates DBA Whitney & Co’s holdings in AbbVie were worth $4,243,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Diversified Trust Co raised its position in AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after acquiring an additional 10,891 shares during the period. Railway Pension Investments Ltd raised its position in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after acquiring an additional 211,800 shares during the period. Public Sector Pension Investment Board raised its position in AbbVie by 17.0% in the third quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company’s stock worth $241,888,000 after acquiring an additional 151,644 shares during the period. Vanguard Group Inc. raised its position in AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after acquiring an additional 448,554 shares during the period. Finally, Thornburg Investment Management Inc. raised its position in AbbVie by 25.5% in the third quarter. Thornburg Investment Management Inc. now owns 401,760 shares of the company’s stock worth $93,024,000 after acquiring an additional 81,625 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several research reports. Evercore lowered their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. William Blair reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Canaccord Genuity Group initiated coverage on shares of AbbVie in a research report on Monday, April 20th. They issued a “buy” rating and a $262.00 price target on the stock. UBS Group lowered their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Finally, Royal Bank Of Canada assumed coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $252.38.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 revenue beat and companyraised full?year adjusted EPS guidance, driven by strong Skyrizi and Rinvoq sales and strength in neuroscience (Botox/Vraylar). That top?line beat and guidance lift are the main reasons the stock is trading higher today. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: AbbVie filed for FDA approval to expand Rinvoq (upadacitinib) to severe alopecia areata and reported strong Phase 3 data—successful label expansion would broaden a high?growth franchise and support longer?term revenue upside. AbbVie Submits Application to FDA for Upadacitinib
• Neutral Sentiment: AbbVie took a strategic option/warrant position with Kestrel (KRAS program) and continues external R&D partnerships (e.g., EvolveImmune milestone) — these expand oncology exposure but are longer?dated potential drivers rather than immediate EPS levers. AbbVie sinks talons into KRAS with right to buy Kestrel
• Negative Sentiment: Adjusted EPS was reported at $2.65 — while many outlets framed results as a beat on revenue and guidance, EPS compared mixedly to different consensus numbers (some providers showed a slight miss/on?par), which has created some investor push?pull and intra?day volatility. AbbVie (ABBV) Tops Q1 Earnings and Revenue Estimates
• Negative Sentiment: Erste Group slightly trimmed its FY2026 and FY2027 EPS forecasts (FY26 to $14.13 from $14.55; FY27 to $16.10 from $16.16) — modest analyst downgrades add downward pressure, though cuts are small relative to the company’s raised 2026 guidance range. Erste Group analyst note (via MarketBeat)

AbbVie Trading Up 3.3%

Shares of NYSE:ABBV opened at $204.20 on Thursday. The company has a 50 day moving average of $214.80 and a 200 day moving average of $221.67. The stock has a market cap of $361.06 billion, a P/E ratio of 86.53, a P/E/G ratio of 0.71 and a beta of 0.38. AbbVie Inc. has a 12 month low of $176.57 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, missing analysts’ consensus estimates of $3.01 by ($0.36). AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the firm earned $2.46 EPS. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. On average, equities analysts forecast that AbbVie Inc. will post 14.21 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.